Pakistan is currently facing a severe crisis in its healthcare sector, with medicine prices soaring at an alarming rate. This price surge has been triggered by the recent suspension of trade between India and Pakistan, following a terrorist attack in Jammu and Kashmir's Pahalgam area, which claimed the lives of 26 people. The attack, carried out by the Pakistan-backed terrorist group Lashkar-e-Taiba's offshoot, The Resistance Front (TRF), led to India's immediate and severe response, including the suspension of all trade ties with Pakistan.

Impact of the Trade Shutdown on Pakistan's Pharmaceutical Sector

Pakistan’s pharmaceutical sector is deeply reliant on India, which supplies over 60 percent of the country's pharmaceutical raw materials, Active Pharmaceutical Ingredients (APIs), and finished medicines. These include critical treatments like anti-rabies serums, MMR vaccines, monoclonal antibodies, and anti-snake-venom. According to reports from ARY News, the prices of medicines in Pakistan had already risen by 14.15 percent and health services had become more expensive by 15.22 percent. However, the total suspension of trade is expected to cause an even more severe increase in medicine prices, which could skyrocket by up to ten times.

As Pakistan struggles to find alternative suppliers for these critical drugs, replacing Indian APIs will be a significant challenge. The cost of Western pharmaceutical alternatives is much higher, and Pakistan's ability to produce or import these alternatives quickly is limited. Testing and regulatory approval for new drugs can take months, meaning critical shortages of essential medicines are inevitable.

Regulatory Concerns and Public Outcry

The situation has led to widespread concern within Pakistan. The Drug Regulatory Authority of Pakistan (Drap) has been criticized for deregulating medicine prices, which many believe has worsened the healthcare crisis. Dr. Muhammad Aleem Akhter, a former deputy director at Drap, has publicly called on Prime Minister Shehbaz Sharif to take urgent action to regulate medicine prices, stating that the skyrocketing prices are causing immense public anger. Healthcare is becoming unaffordable for many citizens, and there is increasing frustration against the government's inability to control the situation.

The Economic Ramifications of the Trade Suspension

The trade shutdown has also brought to light Pakistan's dependence on Indian pharmaceutical exports. As per the Global Trade Research Initiative (GTRI), in the period between April and January 2024, India exported approximately $129.55 million worth of organic chemicals and $110.06 million worth of pharmaceutical products to Pakistan. With the trade suspension, these supplies have been cut off, leaving Pakistan with no viable substitute for its medicine imports. The economic impact of this disruption is expected to be devastating for the country’s pharma sector.

The Possibility of Third-Party Imports

In a desperate attempt to mitigate the crisis, Pakistan may look to source medicines from third-party ports, such as Dubai or Sri Lanka. However, even this workaround is not without significant cost increases. Experts suggest that importing Indian medicines through these channels could result in prices rising by up to four times the original cost. This would make already expensive medicines even more out of reach for ordinary Pakistanis. If Pakistan turns to European suppliers, the price increase could be as steep as ten times the current rates.

Conclusion: The Urgent Need for Price Regulation

In light of the worsening situation, there is an urgent call for the government of Pakistan to step in and regulate medicine prices. The ongoing crisis highlights the fragility of Pakistan's pharmaceutical supply chains and the severe impact of geopolitical tensions on everyday life. The rising cost of medicines not only poses a challenge to public health but also threatens to further exacerbate social unrest in the country.

The situation in Pakistan is a reminder of how global trade relationships can have profound implications on the healthcare sector, and how crucial it is for governments to ensure affordable healthcare for their citizens.

The Upcoming IPOs in this week and coming weeks are Srigee DLM, Manoj Jewellers.

The Current active IPO are Wagons Learning, Kenrik Industries, Arunaya Organics.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.